# Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor

> **NCT01096381** · — · TERMINATED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 8 (actual)

## Conditions studied

- Breast Cancer
- Cardiovascular Complications
- Colorectal Cancer
- Fallopian Tube Cancer
- Head and Neck Cancer
- Lung Cancer
- Ovarian Cancer
- Peritoneal Cavity Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **OTHER:** laboratory biomarker analysis
- **OTHER:** questionnaire administration

## Key facts

- **NCT ID:** NCT01096381
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2010-03
- **Primary completion:** 2011-07
- **Final completion:** 2011-08
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** funding withdrawn due to fellow's departure from VICC
- **Last updated:** 2012-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01096381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01096381, "Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01096381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*